Re: At least RVX has a shorter trial timeline than ESPR
posted on
May 06, 2016 03:15PM
Hey fuzzyjr and narmac, right on.
I was reading a press release about Berkshire's annual meeting and it said that Warren Buffet and his vice chairman Mr Munger fielded 5 hours of questions from investors!
Don does not even field 5 questions and lately he has not allowed questions. Investors need to email in their questions and so the broad audience does not hear the responses.
I know I may get my knuckles whacked for this but I still say that for a guy paying himself $800,000 plus per year he should have far more respect for shareholders.
It is certainly the business side that requires some specific plans and communications but as I posted previously perhaps they are in a stage where they can't talk...now I'll take that back. Clearly they can talk and should communicate but their are obvious areas that they cannot discuss such as the specific of potential deals in progress.
Lots of action is happening including the dosing of BETonMACE patients, start of the zen3694 prostate trial, orphan trian, the hiring of the VP IR. Also the zen3694 trial is FDA approved.
Perhaps with the hiring of Mr Paradis as the VP of investor relations we actually will begin to see more respect for shareholders and better communications. Don has a lot on his plate so having the IR function handled by a senior professional will allow Don to focus on very key issues like the next regional deal, raising money and perhaps spending time with BP.
As frustrated as I am with the beginning of this year and the share price there is nothing but positive things happening at RVX and Zenith.
With BDAZ's scientific perspectives on the BET approaches developed by RVX and Zenith and the fact that apabetalone is unique and generates a MACE reduction of 55% I get more pumped everyday by the scientific potential.
Let's hope that RVX hears the message of frustration with communications on the business side.
GLTA
Toinv